Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2416 participants.

Also called NCT03090113

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,416 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03090113
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03090113. Randomized; quadruple masking; primary purpose prevention. Start 2017-05-12 (actual); primary completion 2019-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
Acronym
SPACE
Condition
Embolic Stroke
Intervention (Drug)
Shuxuetong Injection
Intervention (Drug)
Placebo Injection
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct03090113
Content hash
7c363040735b31e8aa307ae778674e44b3a6fb4bcfcb70c8c1caced2398412fc